Journey Medical
DERM
77 hedge funds and large institutions have $85M invested in Journey Medical in 2025 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 35 increasing their positions, 13 reducing their positions, and 7 closing their positions.
169% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 13
143% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 7
37% more capital invested
Capital invested by funds: $61.9M → $85M (+$23.1M)
13% more funds holding
Funds holding: 68 → 77 (+9)
9.35% more ownership
Funds ownership: 42.8% → 52.15% (+9.4%)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $9K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JGC
J. Goldman & Co
New York
|
+$6.26M |
| 2 |
Millennium Management
New York
|
+$3.59M |
| 3 |
IC
Ikarian Capital
Dallas,
Texas
|
+$1.97M |
| 4 |
PFCS
Pale Fire Capital SE
Prague,
Czech Republic
|
+$1.69M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.17M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAM
PVG Asset Management
Golden,
Colorado
|
-$637K |
| 2 |
Envestnet Asset Management
Chicago,
Illinois
|
-$214K |
| 3 |
FPAS
Focus Partners Advisor Solutions
Saint Louis,
Missouri
|
-$179K |
| 4 |
Walleye Capital
New York
|
-$161K |
| 5 |
Kovitz Investment Group Partners
Chicago,
Illinois
|
-$155K |
DERM Hedge Fund Activity: Q4 2025 in Review
77 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in Journey Medical (DERM) for Q4 2025, worth a combined $85M — up 37% from $61.9M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new DERM positions and 7 closed out — a net gain of 10 holders — while 35 added to existing stakes and 13 trimmed.
The largest buyer was J. Goldman & Co, opening a new position worth an estimated $6.26M. The largest seller was PVG Asset Management, cutting an estimated $637K.
- 77 institutional investors held Journey Medical (DERM) as of Q4 2025, up from 68 in Q3 2025.
- Funds reported $85M of Journey Medical stock for Q4 2025, up 37% quarter-over-quarter.
- 17 funds opened new Journey Medical positions in Q4 2025 and 7 closed out, a net change of +10 holders.
- The largest Journey Medical buyer in Q4 2025 was J. Goldman & Co, an estimated $6.26M added.
- The largest Journey Medical seller in Q4 2025 was PVG Asset Management, an estimated $637K sold.
Based on aggregated 13F filings for Q4 2025.